阿摩線上測驗
76.下列敘述何者正確？
(A)AML為成人最常見之急性白血病，其中又以帶有第15及第17對染色體轉位突變的預後最差
(B)AML帶有許多基因突變，皆影響其預後，例如： NPM1、FLT3-ITD皆為不佳的基因突變
(C)因AML極難完全治癒，所有AML的病人皆應接受血液幹細胞移植
(D)第一線治療以化學治療為主，常見處方為「7+3」的處方，包含cytarabine及anthracycline
答案：登入後查看
統計： A(305), B(508), C(75), D(1424), E(0) #3197694
統計： A(305), B(508), C(75), D(1424), E(0) #3197694
詳解 (共 9 筆)
軒
#6119372
7+3 regimen from NCCN
ㅤㅤ
ㅤㅤ
初始治療是誘導化療(induction chemotherapy)，以誘導完全緩解。接下來是鞏固治療(Consolidation therapy)，其中可能包括異基因造血幹細胞移植。完全緩解的標誌是骨髓中原始細胞少於5%。
ㅤㅤ
由於整體表現差以及中度至重度的心臟、腎臟、肝臟或肺部功能障礙，患者可能不適合進行幹細胞移植。
ㅤㅤ
The treatment of AML is based on the patient’s overall health status. The continually improving treatment of AML is best performed at specialized facilities, especially in the remission induction phase. Initial treatment is induction chemotherapy to induce complete remission. Consolidation therapy then occurs, which may include allogeneic hematopoietic stem-cell transplantation. Complete remission means that there are less than 5% blast cells in the bone marrow.
Basic induction is continuous IV infusion of cytarabine for seven days, with daunorubicin or idarubicin given IV for three days. Significant myelosuppression usually occurs, along with bleeding or infections. There is a long latency before recovery of the bone marrow, so close preventive and supportive care is essential. Allogeneic stem-cell transplantation during the first complete remission generally improves results if the patient has intermediate or adverse-risk cytogenetics. About 6–12 weeks are needed to prepare for a stem-cell transplant. Standard high-dose cytarabine consolidation chemotherapy usually continues during this period. A patient may be ineligible for the stem-cell transplantation however, due to poor overall performance, and because of moderate to severe cardiac, kidney, liver, or pulmonary impairment.
Basic induction is continuous IV infusion of cytarabine for seven days, with daunorubicin or idarubicin given IV for three days. Significant myelosuppression usually occurs, along with bleeding or infections. There is a long latency before recovery of the bone marrow, so close preventive and supportive care is essential. Allogeneic stem-cell transplantation during the first complete remission generally improves results if the patient has intermediate or adverse-risk cytogenetics. About 6–12 weeks are needed to prepare for a stem-cell transplant. Standard high-dose cytarabine consolidation chemotherapy usually continues during this period. A patient may be ineligible for the stem-cell transplantation however, due to poor overall performance, and because of moderate to severe cardiac, kidney, liver, or pulmonary impairment.
ㅤㅤ
Ref:
Global Epidemiology of Cancer: Diagnosis and Treatment Nicholas G. Avgeropoulos, Craig Badolato, Jahangir Moini, ISBN: 978-1-119-81718-5, March 2022 656 pages
當化療在癌症治療的初期並在開始放療之前使用時，這被稱為誘導化療(induction chemotherapy.)。誘導化療的目標是縮小腫瘤，為放療做準備。
鞏固化療(Consolidation chemotherapy)則用於針對初期治療後仍然存在於體內的癌細胞。
When chemotherapy is used at the beginning of your cancer treatment and before starting radiation therapy, it’s referred to as induction chemotherapy. The goal of induction chemotherapy is to shrink tumors before beginning radiation therapy.
Consolidation chemotherapy is used to target cancer cells that are still in the body after initial treatment.
11
0
